Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MB 102

Next Previous
Drug Profile

MB 102

Alternative Names: Anti-CD123 chimeric antigen receptor T cell therapy - Mustang Bio; CD123 CAR; CD123 CAR T; CD123-targeted CAR T cell therapy; MB 102 - Mustang Bio; MB-102 CD123 CAR; MB102

Latest Information Update: 12 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Myelodysplastic syndromes

Most Recent Events

  • 28 Mar 2024 Discontinued - Phase-I for Acute myeloid leukaemia (In adolescents, In children, Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
  • 28 Mar 2024 Discontinued - Phase-I for Blastic plasmacytoid dendritic cell neoplasm (In adolescents, In children, Recurrent, Second-line therapy or greater) in USA (IV)
  • 28 Mar 2024 Discontinued - Phase-I/II for Acute myeloid leukaemia (Second-line therapy or greater, In adults) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top